278 related articles for article (PubMed ID: 38536576)
1. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
Tawfiq RK; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
[TBL] [Abstract][Full Text] [Related]
2. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
[TBL] [Abstract][Full Text] [Related]
3. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
4. Managing Waldenström's macroglobulinemia with BTK inhibitors.
Buske C; Jurczak W; Salem JE; Dimopoulos MA
Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930
[TBL] [Abstract][Full Text] [Related]
5. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
6. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
Treon SP; Sarosiek S; Castillo JJ
Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
[TBL] [Abstract][Full Text] [Related]
7. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
Kapoor P; Paludo J; Abeykoon JP
Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
[TBL] [Abstract][Full Text] [Related]
8. Management of Waldenström macroglobulinemia in 2020.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
[TBL] [Abstract][Full Text] [Related]
9. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
10. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Argyropoulos KV; Palomba ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for the treatment of Waldenström macroglobulinemia.
Despina F; Meletios Athanasios D; Efstathios K
Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
[TBL] [Abstract][Full Text] [Related]
13. Waldenström macroglobulinemia: biology, genetics, and therapy.
Paludo J; Ansell SM
Blood Lymphat Cancer; 2016; 6():49-58. PubMed ID: 31360080
[TBL] [Abstract][Full Text] [Related]
14. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
Zanwar S; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
[TBL] [Abstract][Full Text] [Related]
15. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
[TBL] [Abstract][Full Text] [Related]
17. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
[TBL] [Abstract][Full Text] [Related]
18. Current approach to Waldenström Macroglobulinemia.
Ravi G; Kapoor P
Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
[No Abstract] [Full Text] [Related]
20. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
Stephens DM; Byrd JC
Blood; 2021 Sep; 138(13):1099-1109. PubMed ID: 34320163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
